摘要
背景:相关研究已表明微囊泡/外泌体可以利用其在细胞间信息传递的优势改善受体细胞的功能、保护损伤组织、提示疾病发生发展,有望成为多种肺病防治的新策略。目的:探讨微囊泡或外泌体在肺病中的应用进展。方法:在标题和摘要中,以"exosome,microvesicle,microparticle,extracellular vesicles,lung,pulmonary,pneumonic,pulmonary,pulmonic"或"细胞微囊泡,外泌体,肺"为检索词,检索PubMed数据库、中国期刊全文数据库(CNKI)和万方数据库中2007年1月至2017年12月关于细胞来源微囊泡/外泌体应用于肺脏疾病治疗的中英文文献,排除重复及不相关研究。结果与结论:(1)根据纳入和排除标准,最终纳入68篇文献进行整理和进一步分析;(2)微囊泡、外泌体因直径小可避免被吞噬,能维持所携带的mRNA,microRNA和蛋白的活性,便于与周围细胞组织进行信息交流,可作为参与肺脏生理和病理微环境的新型旁分泌介质,在肺脏疾病中的应用颇具前景;(3)有些微囊泡、外泌体含有肺病的特定标志物,可作为诊断疾病或判断预后的依据;(4)有些微囊泡、外泌体携带的生物活性物质有促进血管生成、促细胞增殖、迁移的作用,或可作为调控肺病发生发展的潜在靶点;(5)有些微囊泡、外泌体应用于实验动物呼吸系统疾病模型,可减轻水肿,减少促炎因子分泌,促进损伤修复,较细胞移植疗法更具优势;(6)目前临床上对于微囊泡、外泌体的应用还仅停留在肺病的诊断和预后判断,用于调控干预肺病发展的微囊泡、外泌体仍处在实验室阶段,还需大量基础实验来明确,包括用于治疗肺病的微囊泡、外泌体来源,活性成分,用量疗程等系列问题。
BACKGROUND： Microvesicles/exosomes as mediators for intercellular transfer can improve function of recipient cells, protect damaged tissues and predict the development of diseases. They have the potential to become a new treatment strategy for a variety of lung diseases.
OBJECTIVE： To explore the application of microvesicles/exosomes in lung diseases.
METHODS： The authors retrieved PubMed, CNKI and WanFang databases for relative articles addressing the application of stem cell-derived microvesicles/exosomes in lung diseases published from January 2007 to December 2017. The keywords were “exosome, microvesicle, microparticle, extracellular vesicles, lung, pulmonary, pneumonic, pulmonary, pulmonic” in English and Chinese, respectively. The irrelative and repetitive literatures were excluded.
RESULTS AND CONCLUSION： Finally 68 eligible literatures were enrolled based on the inclusion and exclusion criteria. Microvesicles/ exosomes cannot be phagocytosed because of their small diameter. They play a pivotal role in cell-to-cell communication depending on mRNAs, microRNAs and proteins within them. As a new paracrine protein involved in the physiological and pathological microenvironment, microvesicles/exosomes may be the promising strategy for the diagnosis or prognostic prediction of lung diseases. Microvesicles/exosomes carrying bioactive substances promote angiogenesis, cell proliferation and migration. They are deemed to be a potential target for the modulation of lung diseases. In addition, microvesicles/exosomes can relieve edema, reduce pro-inflammatory cytokine secretion and promote injury repair in animal respiratory disease models. Compared to the traditional therapy, they have more advantages in diagnosis and prognosis of lung diseases. However, the use of microvesicles/exosomes is still at its initial stage. A series of problems, including sources, active constituent and dosage of microvesicles/exosomes, are needed to be resolved in the future
作者
罗登
冉文卓
叶迎春
高凌
Luo Deng;Ran Wen-zhuo;Ye Ying-chun;Gao Ling(Department of Endocrinology,Eastern Branch of Renmin Hospital,Wuhan University,Wuhan 430000,Hubei Province,China;Clinical Laboratory,Wuhan No.1 Hospital,Wuhan 430023,Hubei Province,China)
出处
《中国组织工程研究》
CAS
北大核心
2018年第21期3393-3400,共8页
Chinese Journal of Tissue Engineering Research
基金
武汉大学自主科研资助项目(2042017kf0084)
湖北省自然科学基金项目(2018CFB230)~~
